Institut Regional Du Cancer de Montpellier
Institut Regional Du Cancer de Montpellier
Montpellier, France4 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa. | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, neoplasm, sarcoma | Recruiting | Phase 2 | 2026-06-02 | NCT06022159 | |
| Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Active, not recruiting | Phase 3 | 2026-02-23 | NCT02811861 | |
| Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-02-20 | NCT05378204 | |
| First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors | Solid Tumor, Adult | Recruiting | Phase 1 / Phase 2 | 2024-11-07 | NCT06622486 |